Allison Gatlin is a tech reporter who writes for Yahoo Finance, Antelope Valley Newspapers, Inc., and Investor's Business Daily. She has also been featured in The Bakersfield Californian. Allison covers a wide range of topics in the tech industry, including company news, stock market analysis, and industry trends.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
California City, United States (Local)
Not enough data
Allison Gatlin's coverage primarily focuses on the healthcare and pharmaceutical industry, with an emphasis on investment analysis and data citations. To effectively reach out to her, consider providing insights related to new drug developments, company financials, or market trends within the healthcare and pharmaceutical sector.
Given Allison's focus on investment analysis and data-driven reporting, she may be receptive to pitches that include statistical evidence or exclusive access to pertinent industry data that supports a particular trend or development in the healthcare and pharmaceutical field.
While Allison does not have a specific geographic focus mentioned, her coverage indicates a global view of the healthcare and pharmaceutical industry. Therefore, pitches should encompass international as well as domestic perspectives when relevant.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Allison Gatlin
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
By: Allison Gatlin
BridgeBio Pharma BBIO ) snagged Food and Drug Administration approval for a rival to Pfizer 's ( PFE ) blockbuster heart drug, and BridgeBio stock catapulted by double digits.
By: Allison Gatlin
Is Pfizer stock a sell after shares skidded on the news Trump selected Kennedy to take over HHS? Is PFE stock now a sell?
CALIFORNIA CITY — In a special meeting called barely 24 hours prior — the statutory requirement for notification — the City Council on Monday morning narrowly approved the job description
By: Allison Gatlin
Amgen AMGN ) stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly 's ( LLY ) blockbuster, Zepbound.
By: Allison Gatlin
The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.
By: Allison Gatlin
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.
By: Allison Gatlin
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics.
By: Allison Gatlin
Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a buy?
LANCASTER — For some 30 years, the one-of-a-kind aircraft now known as the X-62A VISTA has been aiding in cutting-edge flight test, mimicking myriad other aircraft and part of the Air Force Test Pilot School at Edwards Air Force Base.
(833) 317-6278 
